NCT00077324 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Grogan EL, Deppen SA, Ballman KV, et al
: Accuracy of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial. [Abstract] J Clin Oncol 30 (Suppl 15): A-7008, 2012.
Harpole D, Ballman KV, Oberg AL, et al
: Proteomic analysis for detection of NSCLC: results of ACOSOG Z4031. [Abstract] J Clin Oncol 29 (Suppl 15): A-7003, 2011.
Harpole DH, Meyerson SL
Lung cancer staging: proteomics. Thorac Surg Clin. 2006 Nov;16(4):339-43. Review.

Use Of Proteomic Analysis Of Serum Samples For Detection Of Non-Small Cell Lung Cancer

Clinical trial NCT00077324 - References